Crown Bioscience Showcases Dramatic Proficiency in PDX Models and Emerging Expertise in Immune-Oncology
(Thomson Reuters ONE) -
Post AACR Immuno-Oncology Scientific Advancements
SANTA CLARA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554)
and a global drug discovery and development services company providing
translational platforms to advance oncology and metabolic disease research,
announces depth and breadth of technologies that ignite and accelerate the
development of new immune-oncology drug discovery.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/71dfadf0-8256-43cd-bafb-
c429a8d37457
CrownBio scientific contribution to AACR:
* Technology which engrafts human immune cells into immunocompromised animals.
When tested with immune activating agents, both short-term (PBMC) and long-
term (CD34+ stem cell) engraftment strategies demonstrate robust anticancer
activity.
* Syngeneic models - both in vitro and in vivo data utilizing their
MuScreen(TM) platform, a large panel of well-characterized and validated
syngeneic models, employed to test the activity of immune modulating
anticancer drugs.
* Utilization of RNASeq data providing expression and mutation data from 18
cell lines. Investigators leverage this data to test both targeted therapy
and immune-modulatory therapy in combination, thus providing rationale for
clinical investigation.
* In vivo, the MuScreen platform enables an agnostic investigation of a
compound's activity and mechanism of action. MuScreen data can be followed-
up with additional pharmacology studies, such as immunophenotyping, or
bioluminescent assessment of metastatic burden.
"Our diligent focus on innovation, and continued scientific advancement charter
unprecedented discovery in our immuno-oncology portfolio," said Jean-Pierre
Wery, CEO of CrownBio. "The robust contribution at this year's annual meeting of
the American Association for Cancer Research, on the part of our scientific
team, validates an unwavering commitment to develop therapies that will impact
the way cancer is treated."
CrownBio can be located at ASCO Booth #17071. To schedule a meeting with our
scientific leadership visit: https://www.crownbio.com/asco-meeting-req
For more information on CrownBio's commitment to furthering the field of
oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology and metabolic disease
research. With an extensive portfolio of relevant models and predictive tools,
Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing(at)crownbio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Datum: 01.06.2017 - 11:14 Uhr
Sprache: Deutsch
News-ID 545694
Anzahl Zeichen: 3641
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crown Bioscience Showcases Dramatic Proficiency in PDX Models and Emerging Expertise in Immune-Oncology"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
